case_images: PMC7680184_01
case_images: Clinical history of the patient. Treatment and molecular testing is indicated in the figure.
case_images: OTT-13-11849-g0001.jpg
case_images: PMC7680184_01_OTT-13-11849-g0001.jpg
case_images: f0001
case_images: After 5 cycles of treatment, liver lesions were significantly decreased and radiograph revealed PR (Figure 1). Two cycles of maintenance therapy were conducted with capecitabine (1.5g bid d1-14) and bevacizumab (500mg d1 q3w) in May 2019 (Figure 1).
case_images: Tumor marker levels of the patient during treatment.
case_images: OTT-13-11849-g0002.jpg
case_images: PMC7680184_01_OTT-13-11849-g0002.jpg
case_images: f0002
case_images: CEA measurement decreased from 100ng/mL to 30ng/mL (Figure 2).
case_images: CT images of the patient before (A) and after (B and C) the regorafenib and nivolumab combination treatment.
case_images: OTT-13-11849-g0003.jpg
case_images: PMC7680184_01_OTT-13-11849-g0003.jpg
case_images: f0003
case_images: However, CT scanning revealed an abdominal disease progression in liver in late June (Figure 3). Until late August 2020, the patient's disease evaluation was PR with more than 12-month PFS (Figure 3).